{
    "nct_id": "NCT04655118",
    "official_title": "A Phase 2 Multicenter Study of TL-895 in Subjects With Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis",
    "inclusion_criteria": "* Adults ≥18 years of age\n* Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician according to the World Health Organization (WHO) criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2\n* Adequate hematologic, hepatic, and renal functions\n* MF symptoms as defined by having at least 2 symptoms with an average baseline (Day -7 to Day -1) score of at least 1 for each of the 2 symptoms per MFSAF v4.0\n* Cohort 3 only: Ineligibility for JAKi treatment with a platelet count of ≥ 25 and < 50 x 10^9/L\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with any BTK or BMX inhibitors\n* Prior treatment with JAKi within 28 days prior to study treatment\n* Prior splenectomy or splenic irradiation within 24 weeks prior to first dose of study treatment\n\nCohort 5\n\nKey Inclusion Criteria:\n\n* Adults ≥18 years of age\n* Confirmed diagnosis of ISM as defined by WHO diagnostic criteria based on review of bone marrow biopsy pathology report results\n* Subject must have moderate-to-severe symptoms\n\nKey Exclusion Criteria:\n\n* Prior treatment with any BTK or BMX inhibitors\n* Prior treatment with Avapritinib, bezuclastinib, or BLU-263/elenestinib\n* Diagnosis with another myeloproliferative disorder",
    "miscellaneous_criteria": "Cohorts 1-3\n\nKey"
}